DNA RNA and Cells

04 Jun 2023 Allogene Therapeutics Presents Updated ALLO-501/501A Phase 1 Data in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting
04 Jun 2023 Gracell Biotechnologies Presents Updated Data of Deep and Durable Responses for FasTCAR-T GC012F in Relapsed/Refractory Multiple Myeloma at 2023 ASCO Annual Meeting
02 Jun 2023 T-knife Therapeutics Presents Preclinical Data on the Anti-Tumor Activity of TK-8001 at ISCT Annual Meeting
02 Jun 2023 Ionis announces positive donidalorsen late-stage clinical progress in HAE
02 Jun 2023 Sirnaomics Dosed the First Patient in Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Treatment
01 Jun 2023 Triumvira Immunologics Highlights Positive Phase 1 Clinical Data on TAC01-HER2 in Solid Tumors at ASCO 2023 Annual Meeting
01 Jun 2023 Precision BioSciences Provides Update on Allogeneic CAR T Programs and Regulatory Path Forward
31 May 2023 SNIPR Biome reports positive clinical interim results for groundbreaking, first-in-human, CRISPR-based microbial gene therapy
31 May 2023 A2 Bio Announces First Patient Dosed in Phase 1 Clinical Trial of A2B530, a Novel Cell Therapy for the Treatment of Colorectal, Pancreatic and Non-small Cell Lung Cancers
29 May 2023 Collaborators at the Keio and Osaka Universities Present Key Non-Clinical Data with Stable/Functional-Induced Regulatory T Cells (S/F-iTregs) in Autoimmune Disease Models
26 May 2023 Iovance Biotherapeutics Announces U.S. Food and Drug Administration Acceptance of the Biologics License Application of Lifileucel for the Treatment of Advanced Melanoma
26 May 2023 Genelux Corporation Announces Publication of Positive Topline Data from Phase 2 VIRO-15 Trial Evaluating Olvimulogene Nanivacirepvec (Olvi-Vec) in Platinum-Resistant or Refractory Ovarian Cancer in the Journal of the American Medical Association (JAMA) On
26 May 2023 AffyImmune Therapeutics Announces Positive Safety and Early Efficacy Results from Phase 1 Study of AIC100 CAR T Cells in Anaplastic and Advanced Thyroid Cancers at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
26 May 2023 Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel) is First and Only CAR T to Deliver Deep and Durable Efficacy in Pivotal Multicenter Trial in Relapsed or Refractory Chronic Lymphocytic Leukemia, Based on Data Presented at ASCO 2023
26 May 2023 Affini-T Therapeutics to Present AFNT-211 T Cell Product Attributes Targeting KRAS G12V at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
26 May 2023 Artiva Biotherapeutics Presents Initial Data from First-in-Human Phase 1/2 Clinical Trial of AB-101 at the 2023 ASCO Annual Meeting
25 May 2023 Transgene and BioInvent Report Positive Phase Ia Data on Oncolytic Virus BT-001 in Solid Tumors
25 May 2023 Legend Biotech Announces Submission to the European Medicines Agency for Expanded Use of CARVYKTI® (ciltacabtagene autoleucel)
24 May 2023 Wave Life Sciences Announces Topline Results from Phase 1b/2a FOCUS-C9 Study of WVE-004 for C9orf72-associated Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
24 May 2023 ReNAgade Therapeutics Launches with over $300 Million in Series A Financing To Unlock the Limitless Potential of RNA Medicine
23 May 2023 Acepodia Announces First Patient Dosed in Phase 1 Clinical Trial of ACE1831, an Anti-CD20 Armed Allogeneic Gamma Delta T-cell Therapy in Development to Treat Patients with Non-Hodgkin's Lymphoma
22 May 2023 Immix Biopharma Announces Positive NXC-201 Clinical Results at ASGCT: 100% Overall Response Rate in DARZALEX-Relapsed/Refractory AL Amyloidosis with Zero ICANs in Ongoing NEXICART-1 Phase 1b/2a Clinical Trial
20 May 2023 Taysha Gene Therapies Presents Preclinical Data on TSHA-102 for Rett Syndrome Demonstrating Cellular Regulation of MeCP2 Expression in Key Mouse Models at the American Society of Gene and Cell Therapy 26th Annual Meeting
20 May 2023 Candel Therapeutics Announces New Data from Ongoing Phase 1 Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting
20 May 2023 Orchard Therapeutics Announces Positive Clinical and Preclinical Data in Programs Targeting Neurometabolic and CNS Disorders at ASGCT

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2022 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up